2009 unambiguously marked a thawing of the bio IPO market – who froze up at the tail end of 2007 – by featuring six offerings, and a seventh filed that may still travel along the neon lights of the midtown Manhattan Nasdaq ticker before we see Dick Clark and friends ring in 2010 from just [...]
